查看購物車
  • Simplified Chinese
  • English
2021-2031年阿茲海默症藥物市場規模及預測、全球及區域佔有率、趨勢和成長機會分析報告涵蓋範圍：按藥物類別和最終用戶（醫院藥房、零售藥房和線上藥房）分類
市場調查報告書
商品編碼
1858585

2021-2031年阿茲海默症藥物市場規模及預測、全球及區域佔有率、趨勢和成長機會分析報告涵蓋範圍：按藥物類別和最終用戶（醫院藥房、零售藥房和線上藥房）分類

Alzheimer's Drugs Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class and End User (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
出版日期: | 出版商: The Insight Partners | 英文 215 Pages | 訂單完成後即時交付

價格

阿茲海默症藥物市場預計將從2024年的82.4億美元成長到2031年的263.7億美元，2025年至2031年間的複合年成長率（CAGR）預計為13.6%。人口老化、阿茲海默症患者病率上升以及診斷和早期檢測技術的進步是推動阿茲海默症藥物市場規模擴張的重要因素。然而，疾病改善療法的高昂成本阻礙了阿茲海默症藥物市場的發展。

公私合作及經費支持能夠有效整合政府機構、學術中心、製藥公司和慈善基金會的資源，加速有效療法的研發。美國國立衛生研究院 (NIH) 的「加速藥物研發夥伴關係-阿茲海默症」（AMP-AD 2.0）計畫已吸引大量資源，推動阿茲海默症的研究。該計畫整合了 NIH 超過 6,100 萬美元的公共投資，以及衛材 (Eisai) 和武田 (Takeda) 等製藥公司的投資。該計畫旨在促進資料和精準醫療策略的開放共享，加速生物標記的發現和治療標靶的驗證。諸如 BrightFocus 和 Part the Cloud 等慈善項目已投入數百萬美元用於早期研究，以支持具有前瞻性的項目，這些項目已從風險投資和製藥公司合作等多個管道獲得超過 10 億美元的資金。在州一級，擬建的德克薩斯州失智症預防與研究所（DPRIT）將在十年內投入高達30億美元用於失智症研究，促進合作，從而推動當地生物技術的發展和臨床突破。此外，大型製藥公司和生技公司之間的合作日益增多，例如渤健（Biogen）與衛材（Eisai）合作，共同開發和銷售阿茲海默症療法，匯集資源和能力，加快產品進入市場的速度。這些公私合作項目降低了財務風險，加強了資源共享，降低了藥物研發的風險，並縮短了研發週期。在商業層面，這些計畫豐富了阿茲海默症藥物的研發管線，刺激了生物技術和製藥公司的投資，並增強了監管機構和公眾對新藥的信任。這些合作關係和資金流入正在加速疾病改善療法的研發，並支撐著一個更創新驅動的阿茲海默症藥物市場。

基於最終用戶的洞察

根據最終用戶，阿茲海默症藥物市場可分為醫院藥房、零售藥房和線上藥房。 2024年，醫院藥局佔據了最大的阿茲海默症藥物市場。尤其是在以住院治療為主要診斷和治療啟動方式的地區，醫院藥房負責分發和管理阿茲海默症藥物。由於阿茲海默症的治療管理十分複雜，需要神經科醫生或老年科醫生的專業診治，因此醫院藥房在處方、配藥以及為患者和護理人員提供治療方案建議方面發揮著至關重要的作用。醫院藥房阿茲海默症藥物的銷售受到報銷政策和不斷變化的治療建議的影響。醫院仍將膽鹼酯酶抑制劑（ChEI）作為輕度至中度阿茲海默症的第一線對症治療藥物。由於其療效和耐受性良好，多奈哌齊（安理申）作為全球處方量最大的膽鹼酯酶抑制劑，已被納入醫院的處方集。利伐斯的明具有靈活的給藥方式，尤其適用於便於病人監測的醫院環境。它有口服膠囊和透皮貼片兩種劑型。醫院藥局透過提供用藥諮詢、依從性監測和副作用管理等服務來提升價值——這些服務對於阿茲海默症治療至關重要。此類服務使醫院藥房的產品和服務區別於零售藥房，並有助於改善患者預後，從而可能推動對特定劑型（例如，利伐斯的明貼劑以提高依從性）的需求，進而促進阿茲海默症藥物市場的成長。

在編寫阿茲海默症藥物市場報告時，參考的主要和次要來源包括世界衛生組織和美國醫療保險。

目錄

第1章：引言

第2章：執行概要

  • 分析師市場展望
  • 市場吸引力

第3章：研究方法

  • 二手研究
  • 初步研究
    • 假設的提出：
    • 宏觀經濟因素分析：
    • 發展基礎數字：
    • 數據三角測量：
    • 國家層面資料：
  • 假設和局限性

第4章：阿茲海默症藥物市場概況

  • 概述
  • PEST分析

第5章：阿茲海默症藥物市場－關鍵市場動態

  • 阿茲海默症藥物市場—關鍵市場動態
  • 市場促進因素
    • 人口老化與阿茲海默症患者病率上升
    • 改進診斷和早期檢測
  • 市場限制
    • 疾病修飾療法（DMTs）成本高昂
  • 市場機遇
    • 聯合療法和輔助治療
  • 未來趨勢
    • 公私合作與資金成長
  • 駕駛員和安全帶的影響：

第6章：阿茲海默症藥物市場－全球市場分析

  • 2021-2031年阿茲海默症藥物市場收入
  • 阿茲海默症藥物市場預測分析

第7章：阿茲海默症藥物市場分析－依藥物類別分類

  • 膽鹼酯酶抑制劑
  • NMDA受體拮抗劑
  • 複方藥物
  • 其他

第8章：阿茲海默症藥物市場分析－以最終用戶分類

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第9章：阿茲海默症藥物市場—地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第10章：競爭格局

  • 關鍵參與者熱力圖分析
  • 公司市佔率分析，2024 年

第11章：行業概況

  • 概述
  • 新產品開發與核准
  • 合作關係
  • 其他商業策略

第12章：公司簡介

  • Novartis AG
  • Daiichi Sankyo Co Ltd
  • Johnson & Johnson
  • Pfizer Inc
  • Merck & Co Inc
  • Biogen Inc
  • Merz Pharma GmbH & Co KGaA
  • Eli Lilly and Co
  • Otsuka Pharmaceuticals Co Ltd
  • AbbVie Inc

第13章：附錄

Product Code: TIPRE00015800

The Alzheimer's drugs market size is expected to grow from US$ 8.24 billion in 2024 to US$ 26.37 billion by 2031; it is projected to register a CAGR of 13.6% during 2025-2031. The aging population & rising Alzheimer's prevalence, and improved diagnostics & early detection are noteworthy factors contributing to the expansion of the Alzheimer's drugs market size. However, the high cost of disease-modifying therapies hinders the Alzheimer's drugs market.

Public-private partnerships and funding leverage the resources of government organizations, academic centers, pharmaceutical firms, and philanthropic foundations to speed up the creation of effective treatments. The US National Institutes of Health (NIH)'s Accelerating Medicines Partnership-Alzheimer's Disease (AMP-AD 2.0) has attracted a substantial number of resources to drive research on Alzheimer's. This initiative integrates more than US$61 million of public investment from the NIH with investment from pharmaceutical firms like Eisai and Takeda. This project promotes open sharing of data and precision medicine strategies, accelerating biomarker discovery and validation of therapeutic targets. Philanthropic initiatives like BrightFocus and Part the Cloud have invested millions in early-stage research, backing forward-thinking projects which have secured more than a billion dollars in funding from multiple sources, ranging from venture capital to pharma partnerships. At the state level, the proposed Texas Dementia Prevention and Research Institute of Texas (DPRIT) would commit up to US$3 billion over ten years to dementia research, fostering collaborations that might spur local biotech expansion and clinical breakthroughs. Furthermore, partnerships among big pharma and biotechs are on the rise, such as with Biogen in partnership with Eisai to co-develop and market Alzheimer's therapies, pooling resources and capabilities to drive faster entry into markets. These public-private initiatives mitigate financial risks and enhance resource sharing, de-risking drug development, and compress timelines. Commercially, they diversify the Alzheimer's drugs pipeline, stimulate investment from biotech and pharma, and boost regulatory and public trust in new medicines. These partnerships and funding influxes are accelerating disease-modifying treatments and underpinning a more innovation-driven Alzheimer's drugs market.

End User-Based Insights

Based on end user, the Alzheimer's drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest Alzheimer's drugs market share in 2024. Particularly in areas where hospital-based care is the main method of diagnosis and treatment initiation, hospital pharmacies distribute and oversee AD medications. Hospital pharmacies are essential resources for prescribing, dispensing, and advising patients and caregivers on therapeutic options due to the complexity of managing Alzheimer's disease, which calls for specialized neurologists or geriatricians. The sale of Alzheimer's medications in hospital pharmacies is influenced by reimbursement regulations and changing treatment recommendations. Hospitals continue to prescribe ChEIs as the first-line symptomatic treatments for mild to moderate AD. Because of its demonstrated effectiveness and tolerability, donepezil (Aricept), the most prescribed ChEI worldwide, is included in hospital formularies. Rivastigmine provides the dosing flexibility preferred in hospital settings where patient monitoring is practical. It is available as oral capsules and transdermal patches. Hospital pharmacies add value by providing medication counseling, adherence monitoring, and managing side effects-services critical in Alzheimer's treatment. Such programs differentiate hospital pharmacy offerings from retail outlets and support patient outcomes, potentially driving demand for specific formulations (e.g., rivastigmine patches for better compliance), thereby fueling the Alzheimer's drugs market growth.

The World Health Organization and Medicare are among the primary and secondary sources referred to while preparing the Alzheimer's drugs market report.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Analyst Market Outlook
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:
  • 3.3 Assumptions and Limitations

4. Alzheimer's Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Alzheimer's Drugs Market - Key Market Dynamics

  • 5.1 Alzheimer's Drugs Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Aging Population & Rising Alzheimer's Prevalence
    • 5.2.2 Improved Diagnostics & Early Detection
  • 5.3 Market Restraints
    • 5.3.1 High Cost of Disease-Modifying Therapies (DMTs)
  • 5.4 Market Opportunities
    • 5.4.1 Combination Therapies and Adjunct Treatments
  • 5.5 Future Trends
    • 5.5.1 Public-Private Collaborations and Funding Growth
  • 5.6 Impact of Drivers and Restraints:

6. Alzheimer's Drugs Market - Global Market Analysis

  • 6.1 Alzheimer's Drugs Market Revenue (US$ Million), 2021-2031
  • 6.2 Alzheimer's Drugs Market Forecast Analysis

7. Alzheimer's Drugs Market Analysis - by Drug Class

  • 7.1 Cholinesterase Inhibitors
    • 7.1.1 Overview
    • 7.1.2 Cholinesterase Inhibitors: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 NMDA Receptor Antagonists
    • 7.2.1 Overview
    • 7.2.2 NMDA Receptor Antagonists: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Combination Drugs
    • 7.3.1 Overview
    • 7.3.2 Combination Drugs: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. Alzheimer's Drugs Market Analysis - by End User

  • 8.1 Hospital Pharmacies
    • 8.1.1 Overview
    • 8.1.2 Hospital Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Retail Pharmacies
    • 8.2.1 Overview
    • 8.2.2 Retail Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Online Pharmacies
    • 8.3.1 Overview
    • 8.3.2 Online Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. Alzheimer's Drugs Market - Geographical Analysis

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 North America Alzheimer's Drugs Market Overview
    • 9.2.2 North America: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
      • 9.2.2.1 North America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 9.2.2.1.1 North America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
      • 9.2.2.2 North America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
    • 9.2.3 North America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
      • 9.2.3.1 United States: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.1.1 United States: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.2.3.1.1.1 United States: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.2.3.1.2 United States: Alzheimer's Drugs Market Breakdown, by End User
      • 9.2.3.2 Canada: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.2.1 Canada: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.2.3.2.1.1 Canada: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.2.3.2.2 Canada: Alzheimer's Drugs Market Breakdown, by End User
      • 9.2.3.3 Mexico: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.3.1 Mexico: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.2.3.3.1.1 Mexico: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.2.3.3.2 Mexico: Alzheimer's Drugs Market Breakdown, by End User
  • 9.3 Europe
    • 9.3.1 Europe Alzheimer's Drugs Market Overview
    • 9.3.2 Europe: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
      • 9.3.2.1 Europe: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 9.3.2.1.1 Europe: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
      • 9.3.2.2 Europe: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
    • 9.3.3 Europe: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
      • 9.3.3.1 Germany: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.1.1 Germany: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.3.3.1.1.1 Germany: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.3.3.1.2 Germany: Alzheimer's Drugs Market Breakdown, by End User
      • 9.3.3.2 United Kingdom: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.2.1 United Kingdom: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.3.3.2.1.1 United Kingdom: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.3.3.2.2 United Kingdom: Alzheimer's Drugs Market Breakdown, by End User
      • 9.3.3.3 France: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.3.1 France: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.3.3.3.1.1 France: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.3.3.3.2 France: Alzheimer's Drugs Market Breakdown, by End User
      • 9.3.3.4 Italy: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.4.1 Italy: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.3.3.4.1.1 Italy: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.3.3.4.2 Italy: Alzheimer's Drugs Market Breakdown, by End User
      • 9.3.3.5 Spain: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.5.1 Spain: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.3.3.5.1.1 Spain: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.3.3.5.2 Spain: Alzheimer's Drugs Market Breakdown, by End User
      • 9.3.3.6 Rest of Europe: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.6.1 Rest of Europe: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.3.3.6.1.1 Rest of Europe: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.3.3.6.2 Rest of Europe: Alzheimer's Drugs Market Breakdown, by End User
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Alzheimer's Drugs Market Overview
    • 9.4.2 Asia Pacific: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
      • 9.4.2.1 Asia Pacific: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 9.4.2.1.1 Asia Pacific: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
      • 9.4.2.2 Asia Pacific: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
    • 9.4.3 Asia Pacific: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
      • 9.4.3.1 China: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.1.1 China: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.4.3.1.1.1 China: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.4.3.1.2 China: Alzheimer's Drugs Market Breakdown, by End User
      • 9.4.3.2 Japan: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.2.1 Japan: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.4.3.2.1.1 Japan: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.4.3.2.2 Japan: Alzheimer's Drugs Market Breakdown, by End User
      • 9.4.3.3 India: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.3.1 India: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.4.3.3.1.1 India: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.4.3.3.2 India: Alzheimer's Drugs Market Breakdown, by End User
      • 9.4.3.4 Australia: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.4.1 Australia: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.4.3.4.1.1 Australia: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.4.3.4.2 Australia: Alzheimer's Drugs Market Breakdown, by End User
      • 9.4.3.5 South Korea: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.5.1 South Korea: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.4.3.5.1.1 South Korea: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.4.3.5.2 South Korea: Alzheimer's Drugs Market Breakdown, by End User
      • 9.4.3.6 Rest of APAC: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.6.1 Rest of APAC: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.4.3.6.1.1 Rest of APAC: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.4.3.6.2 Rest of APAC: Alzheimer's Drugs Market Breakdown, by End User
  • 9.5 Middle East and Africa
    • 9.5.1 Middle East and Africa Alzheimer's Drugs Market Overview
    • 9.5.2 Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
      • 9.5.2.1 Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 9.5.2.1.1 Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
      • 9.5.2.2 Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
    • 9.5.3 Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
      • 9.5.3.1 Saudi Arabia: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.1.1 Saudi Arabia: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.5.3.1.1.1 Saudi Arabia: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.5.3.1.2 Saudi Arabia: Alzheimer's Drugs Market Breakdown, by End User
      • 9.5.3.2 South Africa: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.2.1 South Africa: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.5.3.2.1.1 South Africa: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.5.3.2.2 South Africa: Alzheimer's Drugs Market Breakdown, by End User
      • 9.5.3.3 United Arab Emirates: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.3.1 United Arab Emirates: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.5.3.3.1.1 United Arab Emirates: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.5.3.3.2 United Arab Emirates: Alzheimer's Drugs Market Breakdown, by End User
      • 9.5.3.4 Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.4.1 Rest of Middle East and Africa: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.5.3.4.1.1 Rest of Middle East and Africa: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.5.3.4.2 Rest of Middle East and Africa: Alzheimer's Drugs Market Breakdown, by End User
  • 9.6 South and Central America
    • 9.6.1 South and Central America Alzheimer's Drugs Market Overview
    • 9.6.2 South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
      • 9.6.2.1 South and Central America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 9.6.2.1.1 South and Central America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
      • 9.6.2.2 South and Central America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
    • 9.6.3 South and Central America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
      • 9.6.3.1 Brazil: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.6.3.1.1 Brazil: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.6.3.1.1.1 Brazil: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.6.3.1.2 Brazil: Alzheimer's Drugs Market Breakdown, by End User
      • 9.6.3.2 Argentina: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.6.3.2.1 Argentina: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.6.3.2.1.1 Argentina: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.6.3.2.2 Argentina: Alzheimer's Drugs Market Breakdown, by End User
      • 9.6.3.3 Rest of South and Central America: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.6.3.3.1 Rest of South and Central America: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.6.3.3.1.1 Rest of South and Central America: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.6.3.3.2 Rest of South and Central America: Alzheimer's Drugs Market Breakdown, by End User

10. Competitive Landscape

  • 10.1 Heat Map Analysis by Key Players
  • 10.2 Company Market Share Analysis, 2024

11. Industry Landscape

  • 11.1 Overview
  • 11.2 New Product Development and Approvals
  • 11.3 Partnerships
  • 11.4 Other Business Strategies

12. Company Profiles

  • 12.1 Novartis AG
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Daiichi Sankyo Co Ltd
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Johnson & Johnson
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Pfizer Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Merck & Co Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Biogen Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Merz Pharma GmbH & Co KGaA
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Eli Lilly and Co
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Otsuka Pharmaceuticals Co Ltd
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 AbbVie Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Alzheimer's Drugs Market Segmentation
  • Table 2. Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million)
  • Table 3. Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million)
  • Table 4. North America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 5. North America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 6. North America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 7. North America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 8. North America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 9. North America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 10. United States: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 11. United States: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 12. United States: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 13. United States: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 14. United States: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 15. United States: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 16. Canada: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 17. Canada: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 18. Canada: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 19. Canada: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 20. Canada: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 21. Canada: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 22. Mexico: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 23. Mexico: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 24. Mexico: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 25. Mexico: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 26. Mexico: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 27. Mexico: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 28. Europe: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 29. Europe: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 30. Europe: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 31. Europe: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 32. Europe: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 33. Europe: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 34. Germany: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 35. Germany: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 36. Germany: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 37. Germany: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 38. Germany: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 39. Germany: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 40. United Kingdom: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 41. United Kingdom: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 42. United Kingdom: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 43. United Kingdom: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 44. United Kingdom: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 45. United Kingdom: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 46. France: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 47. France: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 48. France: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 49. France: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 50. France: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 51. France: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 52. Italy: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 53. Italy: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 54. Italy: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 55. Italy: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 56. Italy: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 57. Italy: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 58. Spain: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 59. Spain: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 60. Spain: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 61. Spain: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 62. Spain: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 63. Spain: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 64. Rest of Europe: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 65. Rest of Europe: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 66. Rest of Europe: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 67. Rest of Europe: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 68. Rest of Europe: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 69. Rest of Europe: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 70. Asia Pacific: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 71. Asia Pacific: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 72. Asia Pacific: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 73. Asia Pacific: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 74. Asia Pacific: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 75. Asia Pacific: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 76. China: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 77. China: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 78. China: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 79. China: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 80. China: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 81. China: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 82. Japan: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 83. Japan: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 84. Japan: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 85. Japan: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 86. Japan: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 87. Japan: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 88. India: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 89. India: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 90. India: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 91. India: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 92. India: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 93. India: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 94. Australia: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 95. Australia: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 96. Australia: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 97. Australia: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 98. Australia: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 99. Australia: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 100. South Korea: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 101. South Korea: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 102. South Korea: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 103. South Korea: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 104. South Korea: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 105. South Korea: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 106. Rest of APAC: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 107. Rest of APAC: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 108. Rest of APAC: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 109. Rest of APAC: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 110. Rest of APAC: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 111. Rest of APAC: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 112. Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 113. Middle East and Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 114. Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 115. Middle East and Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 116. Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 117. Middle East and Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 118. Saudi Arabia: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 119. Saudi Arabia: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 120. Saudi Arabia: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 121. Saudi Arabia: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 122. Saudi Arabia: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 123. Saudi Arabia: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 124. South Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 125. South Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 126. South Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 127. South Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 128. South Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 129. South Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 130. United Arab Emirates: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 131. United Arab Emirates: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 132. United Arab Emirates: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 133. United Arab Emirates: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 134. United Arab Emirates: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 135. United Arab Emirates: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 136. Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 137. Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 138. Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 139. Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 140. Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 141. Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 142. South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 143. South and Central America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 144. South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 145. South and Central America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 146. South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 147. South and Central America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 148. Brazil: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 149. Brazil: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 150. Brazil: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 151. Brazil: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 152. Brazil: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 153. Brazil: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 154. Argentina: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 155. Argentina: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 156. Argentina: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 157. Argentina: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 158. Argentina: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 159. Argentina: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 160. Rest of South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 161. Rest of South and Central America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 162. Rest of South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 163. Rest of South and Central America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 164. Rest of South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 165. Rest of South and Central America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 166. Heat Map Analysis by Key Players
  • Table 167. Glossary of Terms, Global Alzheimer's Drugs Market

List Of Figures

  • Figure 1. Alzheimer's Drugs Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Alzheimer's Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 5. Alzheimer's Drugs Market Share (%) - by Drug Class (2024 and 2031)
  • Figure 6. Cholinesterase Inhibitors: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. NMDA Receptor Antagonists: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Combination Drugs: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Others: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Alzheimer's Drugs Market Share (%) - by End User (2024 and 2031)
  • Figure 11. Hospital Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Retail Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Online Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Alzheimer's Drugs Market Breakdown by Region, 2024 and 2031 (%)
  • Figure 15. North America: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 16. North America: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 17. United States: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Canada: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Mexico: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Europe: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 21. Europe: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 22. Germany: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 23. United Kingdom: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 24. France: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 25. Italy: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 26. Spain: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 27. Rest of Europe: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 28. Asia Pacific: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 29. Asia Pacific: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 30. China: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 31. Japan: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 32. India: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 33. Australia: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 34. South Korea: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 35. Rest of APAC: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 36. Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 37. Middle East and Africa: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 38. Saudi Arabia: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 39. South Africa: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 40. United Arab Emirates: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 41. Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 42. South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 43. South and Central America: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 44. Brazil: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 45. Argentina: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 46. Rest of South and Central America: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 47. Company Market Share Analysis, 2024